ReviewBiotechnology and bioengineering2026
Application of Transgenic Silk Fibroin to Biomaterials.
Review in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As a biomaterial, silk fibroin (SF) derived from the silkworm Bombyx mori exhibits excellent biocompatibility, controllable biodegradability, minimal inflammatory responses, outstanding mechanical properties, and high processability that enables the formation of various tailored morphologies. However, the properties of natural silk proteins alone may not satisfy all application requirements. To overcome these limitations, researchers have been modifying silk protein genes using genetic engineering and molecular biotechnology to produce novel SFs with specific functions. This approach has expanded the application range of SF and enhanced its overall value. Transgenic (TG) expression technology provides an effective means for functional modification of SF, significantly advancing its applications in biomedical and other fields. This review discusses recent structural studies of B. mori SF, along with the design, production, and validation of targeted TG SFs, as well as the latest developments in TG silk technology. Furthermore, it outlines the significance of TG SF development based on comparisons with conventional silk. In particular, it highlights the advantages of TG SF in wound dressing materials, bone regeneration, and the development of small-diameter artificial vascular grafts. Lastly, we discussed the challenges and limitations that TG silk development currently faces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.